Viatris Inc.

VTRSsupplier

Viatris is a global pharmaceutical company formed from the 2020 merger of Mylan and Pfizer's Upjohn division, focused on expanding access to generic and biosimilar medicines worldwide.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($15.0B)

Datos estáticos (cargando finanzas en tiempo real…)

Developed Markets (45%)

Emerging Markets (30%)

Greater China (12%)

JANZ (Japan, Australia, NZ) (13%)

Composición de segmentos y clientes principales

Detalles del producto

Branded Generics35%

Off-patent branded drugs sold primarily in emerging markets

Complex Generics & Biosimilars25%

Biosimilar versions of Humira, Herceptin, and complex injectables

Generic Pharmaceuticals25%

Standard generic drugs for developed markets

Legacy Brands (Lipitor, EpiPen)15%

Heritage branded products from Pfizer Upjohn and Mylan

Relaciones en la Cadena de Suministro

Socios

Pfizer Inc.

Legacy Pfizer Upjohn product portfolio

Impacto: Medium — spun off from Pfizer

Competidores

AbbVie Inc.

Biosimilar Humira competition

Impacto: Medium — biosimilar erosion of Humira

Clientes Clave

Walgreens Boots Alliance

Generic drug retail distribution

Impacto: Medium — pharmacy channel

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Viatris Inc. impulsado por IA.

Información de la Empresa

Sede Central

Canonsburg, Pennsylvania, USA

Fundación

2020

Empleados

37,000+

Sitio Web

viatris.com

Estado del sector — 제약 / 바이오

Noticias del sector